Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-20
2008-10-14
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010, C514S236500, C514S407000
Reexamination Certificate
active
07435728
ABSTRACT:
This invention relates to pyrazole derivatives of formula (I)or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives.The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
REFERENCES:
patent: 3303200 (1967-02-01), Wolf et al.
patent: 3963742 (1976-06-01), Cross et al.
patent: 4000301 (1976-12-01), Walworth
patent: 4041046 (1977-08-01), Cross et al.
patent: 6750230 (2004-06-01), Corbau
patent: 7141585 (2004-06-01), Corbau
patent: 6969728 (2005-11-01), Sneddon et al.
patent: 0204424 (2002-01-01), None
Fujiwara et al, “Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells” Antiviral Research, vol. 43, pp. 179-189 (1999).
Fine et al, “Proteasome blockers inhibitor TNF-α release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia” Journal of Neuroimmunology, vol. 95, pp. 55-64 (1999).
Suzumura and Sawada, “Effects of Vesnarinone on Cytokine Production and Activation of Murine Microglia” Life Sciences, vol. 64(14), pp. 1197-1203 (1999).
Traber et al, “Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-α-induced□□HIV-1 replication in latently infected OM10.1 and Ach2 cells” International Immunology, vol. 11(2), pp. 143-150 (1999).
Harrison's Principles of Internal Medicine, 13th ed. © 1994 McGraw-Hill, Inc. Health Professions Division, pp. 1566-1618.
Dzvinchuk et al., Chemical Abstracts, vol. 112:77066, 1990.
Kato et al., Chemical Abstracts, vol. 108:93811, 1988.
Kirsten et al., Chemical Abstracts, vol. 105:60431, 1986.
Anderson, A, et al., “The Synthesis Of Azetidine-3-Carboxylic Acid,”J. Org. Chem.,1972, 3953-3955, vol. 37, No. 4.
Seydel, J., et al., “Mode Of Action And Quantitative Structure-Activity Correlations Of Tuberculostatic Drugs Of The Isonicotinic Acid Hydrazide Type,”J. Med. Chem.,1976, 483-492, vol. 19, No. 4.
Patentability Examination of Bollvian Patent Office dated Mar. 11, 2007 for counter-part Bolivian Patent Application No. 220072 (original in Spanish and English translation).
U.S. Appl. No. 09/899,322, filed Jul. 5, 2001, Corbau.
U.S. Appl. 10/832,920, filed Apr. 26, 2004, Corbau.
Jones Lyn Howard
Mowbray Charles Eric
Price David Anthony
Selby Matthew Duncan
Stupple Paul Anthony
Pfizer Inc
Smolizza Christian M.
Tucker Zachary C
Zelson Steve T.
LandOfFree
Pyrazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012937